ARMATA PHARMACEUTICALS, INC. Increase (Decrease) in Deferred Compensation
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Increase (Decrease) in Deferred Compensation of -$148.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredCompensation · last filed 2026-08-12
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in deferred compensation for the quarter ending 2026-06-30 was -$772.00K, a 425.74% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in deferred compensation for the quarter ending 2026-03-31 was $624.00K.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in deferred compensation for the quarter ending 2025-12-31 was $348.00K, a 50.29% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in deferred compensation for the quarter ending 2025-09-30 was $259.00K, a 27.65% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in deferred compensation for fiscal 2025 was -$89.00K, a 105.89% decline from fiscal 2024.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in deferred compensation for fiscal 2024 was $1.51M.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in deferred compensation for fiscal 2023 was -$1.06M, a 233.67% decline from fiscal 2022.
- ARMATA PHARMACEUTICALS, INC. increase (decrease) in deferred compensation for fiscal 2022 was $793.00K, a 68.01% increase from fiscal 2021.
| Period end | Increase (Decrease) in Deferred Compensation 3 month | Increase (Decrease) in Deferred Compensation 6 month | Increase (Decrease) in Deferred Compensation 9 month | Increase (Decrease) in Deferred Compensation 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$772.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$148.00K 10-Q · filed 2026-08-12 | $200.00K derived: sum of 3 quarters · filed 2026-08-12 | $459.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $624.00K 10-Q · filed 2026-05-13 | $972.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.23M derived: sum of 3 quarters · filed 2026-05-13 | $1.47M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $348.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $607.00K derived: sum of 2 quarters · filed 2026-03-25 | $844.00K derived: sum of 3 quarters · filed 2026-08-12 | -$89.00K 10-K · filed 2026-03-25 |
| 2025-09-30 | $259.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $496.00K derived: sum of 2 quarters · filed 2026-08-12 | -$437.00K 10-Q · filed 2025-11-12 | $263.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $237.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$696.00K 10-Q · filed 2026-08-12 | $4.00K derived: sum of 3 quarters · filed 2026-08-12 | $362.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$933.00K 10-Q · filed 2026-05-13 | -$233.00K derived: sum of 2 quarters · filed 2026-05-13 | $125.00K derived: sum of 3 quarters · filed 2026-05-13 | $399.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $1.06M derived: sum of 2 quarters · filed 2026-03-25 | $1.33M derived: sum of 3 quarters · filed 2026-03-25 | $1.51M 10-K · filed 2026-03-25 |
| 2024-09-30 | $358.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $632.00K derived: sum of 2 quarters · filed 2025-11-12 | $812.00K 10-Q · filed 2025-11-12 | -$161.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $274.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $454.00K 10-Q · filed 2025-08-12 | -$519.00K derived: sum of 3 quarters · filed 2025-08-12 | $124.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $180.00K 10-Q · filed 2025-05-14 | -$793.00K derived: sum of 2 quarters · filed 2025-05-14 | -$150.00K derived: sum of 3 quarters · filed 2025-05-14 | $25.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$973.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -$330.00K derived: sum of 2 quarters · filed 2025-03-21 | -$155.00K derived: sum of 3 quarters · filed 2025-03-21 | -$1.06M 10-K · filed 2025-03-21 |
| 2023-09-30 | $643.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $818.00K derived: sum of 2 quarters · filed 2024-11-13 | -$87.00K 10-Q · filed 2024-11-13 | -$64.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $175.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$730.00K 10-Q · filed 2024-08-13 | -$707.00K derived: sum of 3 quarters · filed 2024-08-13 | -$558.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$905.00K 10-Q · filed 2024-05-07 | -$882.00K derived: sum of 2 quarters · filed 2024-05-07 | -$733.00K derived: sum of 3 quarters · filed 2024-05-07 | -$346.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $172.00K derived: sum of 2 quarters · filed 2024-03-21 | $559.00K derived: sum of 3 quarters · filed 2024-03-21 | $793.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $149.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $536.00K derived: sum of 2 quarters · filed 2023-11-14 | $770.00K 10-Q · filed 2023-11-14 | $91.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $387.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $621.00K 10-Q · filed 2023-08-14 | -$58.00K derived: sum of 3 quarters · filed 2023-08-14 | $441.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $234.00K 10-Q · filed 2023-05-11 | -$445.00K derived: sum of 2 quarters · filed 2023-05-11 | $54.00K derived: sum of 3 quarters · filed 2023-05-11 | $376.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$679.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$180.00K derived: sum of 2 quarters · filed 2023-03-16 | $142.00K derived: sum of 3 quarters · filed 2023-03-16 | $472.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $499.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $821.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.15M 10-Q · filed 2022-11-09 | $412.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $322.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $652.00K 10-Q · filed 2022-08-11 | -$87.00K derived: sum of 3 quarters · filed 2022-08-11 | $249.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $330.00K 10-Q · filed 2022-05-12 | -$409.00K derived: sum of 2 quarters · filed 2022-05-12 | -$73.00K derived: sum of 3 quarters · filed 2022-05-12 | -$316.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$739.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$403.00K derived: sum of 2 quarters · filed 2022-03-17 | -$646.00K derived: sum of 3 quarters · filed 2022-03-17 | -$760.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $336.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $93.00K derived: sum of 2 quarters · filed 2021-11-10 | -$21.00K 10-Q · filed 2021-11-10 | -$265.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$243.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$357.00K 10-Q · filed 2021-08-12 | -$601.00K derived: sum of 3 quarters · filed 2021-08-12 | -$859.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$114.00K 10-Q · filed 2021-05-13 | -$358.00K derived: sum of 2 quarters · filed 2021-05-13 | -$616.00K derived: sum of 3 quarters · filed 2021-05-13 | |
| 2019-12-31 | -$244.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$502.00K derived: sum of 2 quarters · filed 2021-03-18 | -$853.00K 10-K · filed 2021-03-18 | |
| 2019-09-30 | -$258.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$609.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | -$351.00K 10-Q · filed 2020-08-13 | |||
| 2018-06-30 | $392.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |